John Gribben, MD, DSc, FRCPath, FMed Sci of Barts Cancer Institute, London, UK discusses novel lymphoma therapies and targets with Owen O’Connor, MD, PhD of Columbia University, New York, NY and Simon Rule, MD of Plymouth University, Plymouth, UK. First, they discuss where the immunological approach to treatment and targeted approach to treatment are heading. Prof. O’Connor believes that they are heading towards combinations; he also warns, however, that we need to be cautious about combinations and possible toxicities. Prof. Rule then discusses the role of BTK inhibitors such as ibrutinib, long-term follow-up, side effects and targets; he further discusses their role specifically in mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL) and Waldenstrom’s macroglobulinemia. Prof. O’Connor then discusses TGR-1202 and toxicities associated with PI3K inhibitors; he also discusses treatment duration, double-hit lymphoma and strategies for treatment as well as combining the drug with with carfilzomib.
Recorded at the 2016 International Workshop on Non-Hodgkin Lymphoma (iwNHL) meeting held in San Diego, CA.